What is Claimed is:

1. A pharmaceutical composition comprising a eutectic of 35%±2% by weight δ-mannitol 65%±2% by weight Cyclobenzaprine HCl.

2. A pharmaceutical composition comprising a eutectic of 65%±2% by weight Cyclobenzaprine HCl and 35%±2% by weight δ-mannitol, and a eutectic of 75%±2% by weight Cyclobenzaprine HCl and 25%±2% by weight β-mannitol.

3. The pharmaceutical composition of claim 1 or 2, wherein the eutectic of 35%±2% by weight δ-mannitol and 65%±2% by weight Cyclobenzaprine HCl melts at 134 °C±3 °C.

4. The pharmaceutical composition of any one of claims 1-3, wherein the Cyclobenzaprine HCl is micronized Cyclobenzaprine HCl.

5. The pharmaceutical composition of any one of claims 1-4, further comprising a basifying agent.

6. The pharmaceutical composition of claim 5, wherein the basifying agent is K_2HPO_4, Na_2PO_4 or anhydrous trisodium citrate.

7. The pharmaceutical composition of any one of claims 1-6, wherein said composition comprises granules.

8. The pharmaceutical composition of claim 7, wherein said granules comprise cyclobenzaprine HCl and mannitol.

9. The pharmaceutical composition of claim 8, wherein said mannitol is β-mannitol and δ-mannitol.

10. The pharmaceutical composition of any one of claims 7-9, wherein said granules comprise an inner layer comprising β-mannitol and an outer layer comprising the eutectic of δ-mannitol and Cyclobenzaprine HCl

11. A method of manufacturing the pharmaceutical composition of any one of claims 1-10, comprising mixing Cyclobenzaprine HCl, mannitol and a solvent.

12. The method of claim 11, wherein said mixing is wet granulation mixing.

13. The method of claim 11 or 12, wherein the solvent is water, an alcohol, or a mixture thereof.

14. The method of claim 13, wherein said alcohol is methanol.

15. The method of claim 13, wherein said alcohol is ethanol.

16. The method of any one of claims 12-15, further comprising drying after said wet granulation.

17. The method of claim 16, wherein said wet granulation and drying are repeated one or more times.

18. The method of any one of claims 12-15, further comprising crystallizing the Cyclobenzaprine HCl-mannitol mixture after said wet granulation.

19. The method of claim 18, wherein said wet granulation and crystallization are repeated one or more times.20. A method of manufacturing the pharmaceutical composition according to any one of claims 1-10, comprising fluid bed drying Cyclobenzaprine HCl and mannitol in the presence of a solvent.

21. The method according to claim 20, wherein the solvent is water, an alcohol, or a mixture thereof.

22. The method of any one of claims 12-21, wherein the pharmaceutical composition comprises the eutectic of 35%±2% by weight δ-mannitol and 65%±2% by weight Cyclobenzaprine HCl and the eutectic melts at 134±3 °C.